Broad Range of Partnered and Proprietary Products


PRODUCT, COLLABORATION PRODUCTS
AND PRODUCT CANDIDATES
THERAPEUTIC
AREA
APPROVED
INDICATION
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Filed
  • Approved

ENHANZE® COLLABORATION APPROVED PRODUCTS

Roche

 
 
 
 
 
 
Herceptin® SC (trastuzumab)
Oncology
Breast Cancer
Approved in EU and other countries outside the U.S.
 
 
 
 
 
 
MabThera® SC (rituximab)
(Outside of U.S.)
Oncology
Multiple blood cancers
Approved for NHL in the EU and OUS;
Approved for CLL in the EU;
Approved for DLBCL, CLL and FL in the U.S.
 
 
 
 
 
 
RITUXAN HYCELA(rituximab)
(rituximab/hyaluronidase human)
(U.S.)
 
 
 
 
 
 

Baxalta

 
 
 
 
 
 
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Immunology
Primary Immunodeficiency
Approved for adults in the EU, U.S., Puerto Rico and Australia; Pediatric indication approved in EU
 
 
 
 
 
 
PRODUCT, COLLABORATION PRODUCTS
AND PRODUCT CANDIDATES
THERAPEUTIC
AREA
RESEARCH
FOCUS
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Filed
  • Approved

ENHANZE® COLLABORATION PRODUCT CANDIDATES

Roche (Total of 9 potential targets)

 
 
 
 
 
 
PERJETA® (pertuzumab)*
Oncology
Breast Cancer
 
 
 
 
 
 
Undisclosed
Undisclosed
Undisclosed
 
 
 
 
 
 
Pfizer (Total of 6 potential targets)
Undisclosed
 
 
 
 
 
 

Janssen (Total of 5 potential targets)

 
 
 
 
 
 
DARZALEX® (daratumumab)
Oncology
Amyloidosis
Smoldering Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
 
 
 
 
 
 
AbbVie (Total of 9 potential targets)
Undisclosed
 
 
 
 
 
 
Lilly (Total of 5 potential targets)
Undisclosed
 
 
 
 
 
 
Bristol-Myers Squibb (Total of 11 potential targets)
PD-1 target
Oncology
 
 
 
 
 
 
Alexion (Total of 4 potential targets)
ALXN1210 SC
Various
 
 
 
 
 
 

All trademarks belong to their respective owners.

*Plans for Phase 3 fixed-dose combination with Herceptin.

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok